NASDAQ:ONTX - Onconova Therapeutics Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$0.41 +0.01 (+2.50 %)
(As of 08/17/2018 01:31 AM ET)
Previous Close$0.43
Today's Range$0.40 - $0.43
52-Week Range$0.33 - $2.83
Volume466,000 shs
Average Volume1.31 million shs
Market Capitalization$33.98 million
P/E Ratio-0.15
Dividend YieldN/A
Beta0.54
Onconova Therapeutics logoOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680

Debt

Debt-to-Equity RatioN/A
Current Ratio0.81
Quick Ratio0.81

Price-To-Earnings

Trailing P/E Ratio-0.15
Forward P/E Ratio-1.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$790,000.00
Price / Sales40.28
Cash FlowN/A
Price / CashN/A
Book Value($1.01) per share
Price / Book-0.41

Profitability

EPS (Most Recent Fiscal Year)($2.68)
Net Income$-24,090,000.00
Net Margins-1,826.64%
Return on EquityN/A
Return on Assets-216.65%

Miscellaneous

Employees25
Outstanding Shares77,610,000
Market Cap$33.98 million

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics shares reverse split on the morning of Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc (NASDAQ:ONTX) released its quarterly earnings data on Tuesday, August, 14th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.01. The biopharmaceutical company had revenue of $0.49 million for the quarter, compared to analyst estimates of $0.52 million. View Onconova Therapeutics' Earnings History.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Onconova Therapeutics.

What price target have analysts set for ONTX?

2 brokerages have issued 1-year price objectives for Onconova Therapeutics' stock. Their forecasts range from $3.00 to $3.00. On average, they expect Onconova Therapeutics' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 631.7% from the stock's current price. View Analyst Price Targets for Onconova Therapeutics.

What is the consensus analysts' recommendation for Onconova Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Onconova Therapeutics.

What are Wall Street analysts saying about Onconova Therapeutics stock?

Here are some recent quotes from research analysts about Onconova Therapeutics stock:
  • 1. Maxim Group analysts commented, "Onconova reported 2Q18 with a net loss of $4.3M and ended the period with $29.5M in cash, runway into 2H19." (8/14/2018)
  • 2. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (7/18/2018)
  • 3. HC Wainwright analysts commented, "Buy-rated Cytori Therapeutics, Inc. (CYTX, $0.70 PT) reported 4Q17 results AMC Thursday, 3/8/2018, and held a corresponding conference call at 5:30pm ET. CYTX posted a top line/ EPS/adj. EBITDA of $1.5M/($0.20)/($2.9)M versus our estimate of $2.0M/($0.10)/($3.3)M and consensus $2.6M/($0.10)/($1.7)M. The revenue miss was primarily due to lower Celution Systems sales in Japan as 4Q government contract revenue through BARDA for the R&D of medical countermeasures for thermal burns of $0.9M was just shy of our $1.0M estimate. BARDA revenues should continue to increase as CYTX gets ready to commence its pilot trial (for additional info, see Quick Note dated 6/1/17). Meanwhile, CYTX’s EPS would have been in line with our projection but the company recognized $4.0M in one-time non-cash expenses related to a beneficial conversion feature for convertible preferred stock. CYTX’s adj." (3/9/2018)

Who are some of Onconova Therapeutics' key competitors?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:
  • Dr. Ramesh Kumar, Co-Founder, CEO & Director (Age 62)
  • Dr. Steven M. Fruchtman, Chief Medical Officer & Pres (Age 67)
  • Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 74)
  • Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 55)
  • Mr. Mark Patrick Guerin, Chief Financial Officer (Age 49)

Has Onconova Therapeutics been receiving favorable news coverage?

Headlines about ONTX stock have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Onconova Therapeutics earned a daily sentiment score of 0.17 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 47.20 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Onconova Therapeutics.

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (4.64%) and Renaissance Technologies LLC (1.06%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, E Premkumar Reddy, Henry S Bienen, Mark Patrick Guerin and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.

Which institutional investors are buying Onconova Therapeutics stock?

ONTX stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P. and Renaissance Technologies LLC. Company insiders that have bought Onconova Therapeutics stock in the last two years include 683 Capital Management, Llc, E Premkumar Reddy, Henry S Bienen, Mark Patrick Guerin and Ramesh Kumar. View Insider Buying and Selling for Onconova Therapeutics.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $0.41.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $33.98 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-24,090,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]


MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  340
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.